Phase 2 Osteoarthritis Trial, Recruiting NCT03984461 Sponsor: Dr. Grant M. Pagdin Condition: Osteoarthritis
Back to Osteoarthritis

Phase 2 Osteoarthritis Trial, Recruiting

NCT03984461
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be able to give written consent and be willing and able to follow all of the study's requirements.
  • You must be male or female and at least 19 years old when you sign the consent form.
  • You must have a confirmed diagnosis of osteoarthritis in a major joint, shown by an X-ray or MRI taken within the past year, with a severity rating of Grade 1, 2, or 3 on a standard scale called the Kellgren & Lawrence scale.

Who may not be able to join:

  • You may not be eligible if your Body Mass Index (BMI) is above 35.
  • You may not be eligible if you have had arthroscopic (keyhole) surgery on the joint being treated within the last 12 months.
  • You may not be eligible if you have had a cortisone or hyaluronic acid (joint fluid) injection in the affected joint within the last 3 months.
  • You may not be eligible if you are unable to temporarily stop blood-thinning medication before the procedure, as directed by your doctor.
  • You may not be eligible if your osteoarthritis is rated as Grade 4 (the most severe level) on the Kellgren & Lawrence scale.
  • You may not be eligible if your platelet count (cells that help blood clot) is below a certain level.
  • You may not be eligible if your hemoglobin level (a measure of red blood cells) is below a certain level.
  • You may not be eligible if you currently have an active infection with a fever or an elevated white blood cell count.
  • You may not be eligible if you currently have an active cancer diagnosis.
  • You may not be eligible if you have an autoimmune condition, such as rheumatoid arthritis or lupus.
  • You may not be eligible if you are currently pregnant; if you become pregnant during the study, you would be withdrawn from treatment and imaging but could still participate in symptom check-ins.
  • You may not be eligible if you have a known allergy to lidocaine, heparin, or epinephrine.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Stephen Rosenfeld, MD, Quorum Review IRB

Phone: 250-717-3200

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Dr. Grant M. Pagdin
Registry
ClinicalTrials.gov
Start date
1 September 2020
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Changes from baseline through to end of study for the Visual Analogue Scale (VAS).; Changes from baseline through to the end of study for the Short Form 12 item version 2 (SF12-v2)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov